BridgeBio Pharma Inc's stock price fell by 7.77% and hit a 5-day low. This decline occurs despite the broader market's positive performance, with the Nasdaq-100 up 0.70% and the S&P 500 up 0.68%. The stock's movement suggests sector rotation as investors may be reallocating their investments.
The decline in BridgeBio's stock price is attributed to sector rotation, as the company prepares for an investor webinar on January 9, 2026, discussing insights into the treatment of achondroplasia and the ongoing PROPEL 3 study. This event aims to enhance investor awareness of the company's clinical progress, but the immediate market reaction reflects a shift in focus among investors.
The implications of this price movement indicate that while the company is making strides in its research and development efforts, the current market dynamics are influencing investor sentiment, leading to a temporary decline in stock value.
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 79.100
Low
69.00
Averages
87.63
High
100.00
Current: 79.100
Low
69.00
Averages
87.63
High
100.00
Barclays
initiated
$157
2026-01-27
New
Reason
Barclays
Price Target
$157
AI Analysis
2026-01-27
New
initiated
Reason
Barclays initiated coverage of BridgeBio with an Overweight rating and $157 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Raymond James
Outperform
initiated
$24
2026-01-09
Reason
Raymond James
Price Target
$24
2026-01-09
initiated
Outperform
Reason
Raymond James initiated coverage of BridgeBio Oncology with an Outperform rating and $24 price target. The rating reflects promising early Phase 1 activity and safety for BBO-8520 in 1L Non-Small Cell Lung Cancer, potent and selective inhibition by pan-KRAS BBO-11818, potential differentiation of BBO-10203 in metastatic breast cancer, and strong capitalization to advance proof-of-concept updates for all assets, the analyst tells investors in a research note. Confidence is tempered by crowded competition in the KRAS inhibitor space, the firm adds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBIO
Unlock Now
Morgan Stanley
Overweight
to
Overweight
downgrade
$20 -> $18
2026-01-08
Reason
Morgan Stanley
Price Target
$20 -> $18
2026-01-08
downgrade
Overweight
to
Overweight
Reason
Morgan Stanley lowered the firm's price target on BridgeBio Oncology to $18 from $20 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Leerink
Outperform
maintain
$75 -> $86
2025-12-15
Reason
Leerink
Price Target
$75 -> $86
2025-12-15
maintain
Outperform
Reason
Leerink raised the firm's price target on BridgeBio to $86 from $75 and keeps an Outperform rating on the shares. Heading into 2026, the firm is refreshing its TTR market outlook after strong launches from BridgeBio's (BBIO) Attruby and Alnylam's (ALNY) Amvuttra. Leerink expects continued robust growth in 2026, supported by end-market tailwinds from improved diagnosis rates leading to earlier treatment, but is keeping tabs on payer/reimbursement dynamics and pace of new patient adds/switches.
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
